Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Capital Expenditures (2018 - 2025)

BioNexus Gene Lab's Capital Expenditures history spans 8 years, with the latest figure at $5483.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 97.25% year-over-year to $5483.0; the TTM value through Sep 2025 reached $40016.0, down 82.13%, while the annual FY2024 figure was $226989.0, 51.94% up from the prior year.
  • Capital Expenditures for Q3 2025 was $5483.0 at BioNexus Gene Lab, down from $21459.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $199189.0 in Q3 2024 and bottomed at -$32191.0 in Q2 2022.
  • The 5-year median for Capital Expenditures is $4022.0 (2024), against an average of $24443.7.
  • The largest annual shift saw Capital Expenditures surged 33400.0% in 2021 before it crashed 4933.48% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $1279.0 in 2021, then plummeted by 2616.89% to -$32191.0 in 2022, then soared by 102.91% to $937.0 in 2023, then soared by 329.24% to $4022.0 in 2024, then surged by 36.33% to $5483.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Capital Expenditures are $5483.0 (Q3 2025), $21459.0 (Q2 2025), and $9052.0 (Q1 2025).